ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1475	National Cancer Institute	Html	en	Adult Primary Liver Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of adult primary liver cancer.	HCC tumors 0.58507 Semin Liver Dis 0.618193 Hepatocellular carcinoma incidence 0.684284 PDQ cancer information 0.577886 American Cancer Society 0.586704 early hepatocellular carcinoma 0.666995 primary biliary cirrhosis 0.576504 chronic liver disease 0.578131 unresectable hepatocellular carcinoma 0.664574 blood flow 0.562662 hepatocellular carcinoma 0.977206 primary liver cancer 0.589429 Natural history 0.564684 cancer information summary 0.576375 risk factors 0.586296 normal liver parenchyma 0.570598 liver disease 0.607293 liver 0.658374 virus-related hepatocellular carcinoma 0.677568 western European patients 0.565566 patients 0.658086 HCC 0.686159 advanced-stage HCC 0.594418 small hepatocellular carcinoma 0.692383 HCC patients 0.615983	HCC worldwide 0.602122 single hepatocellular carcinoma 0.672174 Liver Italian Program 0.573612 early HCC 0.59445 entire liver 0.564284 Liver Diseases 0.560344 Gastroenterol Hepatol 0.566445 AASLD hepatocellular carcinoma 0.670773 untreated hepatocellular carcinoma 0.669362 study 0.562576 HCC detection 0.593776 liver function 0.561177 PUBMED Abstract 0.598546 early-stage HCC 0.580393 class A cirrhosis 0.563518 arterial blood 0.606167 liver transplant 0.559717 cirrhosis 0.620285 hepatitis b virus 0.59513 Abstract 0.629123 cirrhosis type B. 0.576124 Llovet JM 0.573361 cm hepatocellular carcinoma 0.677106 liver resection 0.566362	CLICK HERE
1715	National Cancer Institute	Html	en	Tests to Detect Colorectal Cancer and Polyps	A fact sheet that discusses the advantages and disadvantages of several colorectal cancer screening tests.	standard colonoscopy 0.642704 average risk 0.571434 sigmoidoscopy screening 0.568313 entire colon 0.614214 colorectal polyps 0.605561 abnormal growths 0.57234 colon problems 0.570159 Occult Blood Test 0.556564 early-stage colorectal cancer 0.600935 occult blood tests 0.564372 thorough cleansing 0.581775 asymptomatic colorectal cancer 0.60263 flexible lighted tube 0.561607 colorectal cancer screening 0.734621 flexible sigmoidoscopy screening 0.562785 small polyps 0.567222 digital rectal examination 0.560544 polyps 0.617192 colorectal cancer 0.956004 test 0.736074 new colorectal cancer 0.625336 guaiac FOBT 0.612613 single-specimen guaiac fobt 0.570386 inflammatory bowel disease 0.568257 ) colonoscopy. 0.566733	colon cancer incidence 0.618181 acceptable screening tests 0.563922 fecal occult blood 0.636365 colorectal cancers 0.601521 rectum 0.592026 colon tissue 0.560628 lower colon 0.576523 colon cancer mortality 0.592993 United States 0.573668 Additional procedures 0.566333 colonoscopy screening methods 0.603294 False-positive test results 0.579985 stool sample 0.563739 colorectal cancer incidence 0.613064 colon cancer 0.621651 fecal immunochemical test 0.563508 stool dna test 0.61197 people 0.593294 virtual colonoscopy 0.697133 cancer screening tests 0.581698 family history 0.558032 sigmoid colon 0.589237 colon 0.791161 et al 0.626521	CLICK HERE
1846	National Cancer Institute	Html	es	Tratamiento del carcinoma de corteza suprarrenal (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del carcinoma de corteza suprarrenal.	Compton CC 0.317328 Hammer GD 0.357944 resection vs chemotherapy 0.309791 Sin embargo 0.386449 estadificación ensat 0.311064 largo plazo 0.314068 treatment utilization 0.307637 7th ed 0.317264 estadificación ajcc 0.311961 corteza suprarrenal benignos 0.333736 adrenal cortical carcinoma 0.326878 Instituto Nacional 0.323164 Radiat Oncol Biol 0.331552 Zaggia B 0.315343 Ardito A 0.314362 Terzolo M 0.35082 Basic Science 0.331876 Else T 0.335075 Clinical review 0.338841 corteza suprarrenal benignas 0.333037 ENSAT staging system 0.311888 Arch Surg 0.319608 Griffith K 0.315391 Feng M 0.318852 Fassnacht M 0.481992	Clin Endocrinol Metab 0.365561 estadio ii 0.316817 metástasis pulmonar 0.312599 Pfreundner L 0.316104 Angeli A 0.316386 Cancer Staging Manual 0.333671 adrenocortical carcinoma using 0.342814 National Cancer Institute 0.309404 PDQ Tratamiento 0.316742 New York 0.405075 Physician Data Query 0.30836 adrenocortical carcinoma 0.972403 Oncol Biol Phys 0.332857 Langenbecks Arch Surg 0.312314 Allolio B 0.353761 with adrenocortical carcinoma 0.336171 Byrd DR 0.316426 Union Internationale Contre 0.309764 American Joint Committee 0.309683 Sabolch A 0.315391 Ther Phys Biol 0.311534 Recurrent or metastatic 0.308748 Clinical Concepts 0.340059 AJCC Cancer Staging 0.33628	CLICK HERE
2043	National Cancer Institute	Html	es	Prevención del cáncer de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre los factores que influyen en el riesgo de presentar cáncer de ovario, de trompas de Falopio y primario de peritoneo y sobre las investigaciones dirigidas a la prevención de los mismos.	Obstet Gynecol 0.31235 oral contraceptives 0.309215 factores alimentarios 0.305635 histologic subtype 0.312055 Cancer Cohort Consortium 0.318833 Colorectal Cancer 0.308524 cancer risk factors 0.338538 An Analysis From 0.306638 Lacey JV Jr 0.313268 individual participant meta-analysis 0.306651 American Cancer Society 0.315301 Prospective Investigation into 0.306516 Ovarian Cancer Association 0.322566 Trabert B 0.318769 National Institutes 0.306184 Cancer Prev 0.318672 ovarian cancer 0.962228 bilateral oophorectomy 0.306539 population-based study 0.305827 Natl Cancer Inst 0.339156 múltiples estudios 0.32855 California Teachers Study 0.307709 Health Study Cohort 0.31028 hormone replacement therapy 0.312605 Beral V 0.305906	European Prospective Investigation 0.306439 investigation into cancer 0.318863 SEER Cancer Statistics 0.308163 Cancer Association Consortium 0.318478 cohort study 0.309167 prospectively studied cohort 0.307037 Midwifery Womens Health 0.306899 health study 0.334114 Cancer Facts 0.308362 tumores tipo 0.310257 National Cancer Institute 0.308306 ovarian cancer risk 0.650797 epidemiological studies 0.315154 antecedentes familiares 0.31063 nih-aarp diet 0.308944 carcinomas ováricos tipo 0.305728 Netherlands cohort study 0.308948 Gynecologic Cancers 0.321276 Yang HP 0.306882 Ovarian Cancer Cohort 0.322781 PDQ Genetics 0.322297 hormone-related risk factors 0.30545 Health-AARP Diet 0.307792 Women’s Health Initiative 0.307189	CLICK HERE
3413	National Cancer Institute	Html	en	Treatment Prevents Chemotherapy Side Effects for Children with Cancer	Adding aprepitant to the anti-nausea drug ondansetron, with or without dexamethasone, effectively prevents chemotherapy-induced nausea and vomiting in children.	Lancet Oncology 0.402095 approximately one-quarter 0.400434 Approximately half 0.380915 individual chemotherapy regimens 0.640029 pediatric oncologists 0.386544 primary endpoint 0.376989 accompanying editorial 0.359286 control group 0.648089 chemotherapy 0.797555 highly emetogenic chemotherapy 0.635176 pediatric patients 0.446593 pediatric dosing 0.38895 cancer therapy 0.375879 South Korea 0.360387 Final results 0.390611 poorer outcomes 0.360045 delayed phase 0.536277 well-designed anti-emetic study 0.496684 children 0.367409 pediatric anti-emetic regimens 0.524869 steroid dexamethasone 0.449436 retrospective reports 0.357625 Hyoung Jin Kang 0.507923 treatment-limiting complications 0.376302	moderate risk 0.374131 Richard Gralla 0.361364 vomiting 0.627585 anti-nausea drug 0.394817 clinical trial 0.39616 chemotherapy-induced nausea 0.735879 Fifty-one percent 0.401703 cancer patients 0.390213 trial results 0.359251 aprepitant group 0.947977 complete response 0.53189 study medications 0.371063 febrile neutropenia 0.569771 Seoul National University 0.506591 neurokinin-1 receptor antagonist 0.536858 serotonin receptor 0.391814 neutrophil count 0.368149 Pediatric Oncology Branch 0.516455 chemotherapy regimen patients 0.648708 antiemetic rescue medication—medication 0.520408 common adverse events 0.501689 Secondary endpoints 0.373589 Melinda Merchant 0.355445	CLICK HERE
15647	National Cancer Institute	Html	en	Genomic Data Sharing (GDS) Policy Contact Information	Genomic Data Sharing Policy contact information, including NCI-Designated GPAs by division or center.	GPA assistant 0.93001 Cancer Training 0.249467 Shannon Hughes 0.229368 Sean Hanlon 0.257761 NIH GDS Policy 0.610914 Guidry Auvil Daniela 0.496929 NCI division 0.258673 Anil Wali Emmanuel 0.495613 Program Director 0.234183 Susan Perkins 0.231974 Cancer Genomics 0.271538	Claire Zhu 0.249716 Kathleen Calzone Anjan 0.535993 NCI-specific questions 0.235899 Cancer Epidemiology 0.243639 email GDS 0.354202 Cancer Health Disparities 0.465506 Natalia Abrams 0.263564 Cancer Research 0.254684 Cancer Prevention 0.23825 genomic program administrator 0.461255 Strategic Scientific Initiatives 0.388719	CLICK HERE
15882	National Cancer Institute	Html	es	Cardo mariano (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del cardo mariano como tratamiento para personas con cáncer.	Silybum marianum 0.735385 Agarwal R 0.945743 cell lines 0.375003 cell growth 0.494513 prostate carcinoma du145 0.373715 DNA synthesis 0.442196 carcinoma cell 0.46955 silybum marianum l 0.361146 Inhibitory effect 0.390679 Agarwal C 0.386743 receptor modulator activity 0.356592 Mol Carcinog 0.378538 Cancer Res 0.59348 carcinoma cell growth 0.407562 prostate carcinoma cells 0.4865 Singh RP 0.367955 flavonoid antioxidant 0.678831 active constituent 0.382485 Antiproliferative effect 0.363827 lipid peroxidation 0.585387 Biochem Pharmacol 0.461277 chemopreventive effects 0.369648 cardo lechero 0.365629 patients with 0.374862 cell growth inhibition 0.393232	Sonnenbichler J 0.428511 prostate carcinoma 0.590474 Campos R 0.414926 Pharmacol Res 0.429959 protective effects 0.379153 Biophys Res Commun 0.50103 prostate-specific antigen with 0.369145 carcinoma du145 cells 0.397873 Biochem Biophys Res 0.508991 Silymarin effects 0.38621 Biomed Res Int 0.385769 Clin Biol Res 0.375557 insulin-like growth factor-binding 0.358425 stimulatory effects 0.357205 Zhao J 0.53049 Guerra R 0.490633 with cell growth 0.41107 comparison with 0.378495 silibinin inhibits 0.378656 Planta Med 0.529049 protects against 0.371646 Mutat Res 0.369799 from silybum marianum 0.396284 Res Commun 0.505421	CLICK HERE
16049	National Cancer Institute	Html	en	Managing Costs and Medical Information	People with cancer may face major financial challenges and need help dealing with the high costs of care. Cancer treatment can be very expensive, even when you have insurance. Learn ways to manage medical information, paperwork, bills, and other records.	cancer treatment 0.452926 file folder 0.451204 emergency room 0.448618 medical bills 0.53618 state specific information 0.467913 insurance coverage 0.460494 health care team 0.51276 American Cancer Society 0.460319 payment options 0.46621 non-medical phone calls 0.432178 social worker 0.59281 clinical trials 0.467219 health care providers 0.479775 State Health Insurance 0.507522 cancer care 0.486022 research costs 0.450096 Track daily events 0.441284 Insurance Assistance Service 0.484543 health care costs 0.531061 patient care costs 0.553498 travel costs 0.463012 government health insurance 0.504906 treatment 0.485685 electronic medical record 0.447232 health care bills 0.536309	insurance company pay 0.509196 help finding referrals 0.489042 Cancer Information Service 0.588627 financial issues 0.432149 Health Insurance Assistance 0.617568 special email account 0.433974 sample chart 0.453844 discount drug programs 0.446076 separate folder 0.500544 extra costs 0.480459 bills 0.574419 hospital 0.455427 health care 0.679621 key medical information 0.460671 insurance company 0.914855 costs 0.714673 NCI Cancer Information 0.458766 important medical information 0.475214 human resources department 0.455264 medicine 0.454681 health care coverage 0.489272 insurance companies 0.472181 doctor 0.602384 mobile device 0.452113	CLICK HERE
16247	National Cancer Institute	Html	en	Examining the Effects of Presurgical Treatment for Prostate Cancer	In this study, men diagnosed with androgen-sensitive prostate cancer with intermediate- or high-risk features will be examined with mpMRI, undergo targeted biopsies, and be treated with neoadjuvant androgen deprivation therapy.	prostate tumors 0.614738 mpMRI scans 0.310993 new strategies 0.267582 potential tumor markers 0.311786 clinical trials 0.372782 targeted biopsy samples 0.322875 targeted lesions 0.294339 specific prostate lesions 0.476878 high-risk features 0.288054 newly diagnosed prostate 0.622232 metastatic prostate cancer 0.498919 prostate cancer cells 0.594259 surgically removed organs 0.312098 antiandrogen drug enzalutamide 0.322935 single imaging exam 0.312805 Dr. William Dahut 0.330786 systemic therapy 0.28819 neoadjuvant therapy 0.769289 aggressive prostate cancers 0.483417 protocol summary 0.275419 androgen-deprivation therapy 0.285401 NCI Center 0.275353 magnetic resonance imaging 0.315153 trial contact information 0.309223 United States 0.272406	intensive hormonal therapy 0.397524 high-risk prostate tumors 0.477739 prostatectomy specimens 0.282563 Treating Patients 0.272894 initial mpMRI scans 0.308885 high-risk prostate cancer 0.602491 radical prostatectomy 0.351855 NCI Clinical Trials 0.312784 common malignancy 0.274438 androgen-sensitive prostate cancer 0.480836 potential strategy 0.266185 Cancer Research 0.343151 anatomic imaging 0.268037 drug goserelin actetate 0.309432 targeted biopsies 0.292493 male sex hormones 0.320468 Goserelin Acetate 0.270879 high-risk disease 0.33068 prostate cancer 0.95691 neoadjuvant ADT 0.340784 aggressive disease 0.267926 prostate cancer recurrence 0.502931 specific lesions 0.287557 effective neoadjuvant therapy 0.348548	CLICK HERE
17173	National Cancer Institute	Html	es	Hongos medicinales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de los hongos medicinales como tratamiento para las personas con cáncer.	adjuvant immunochemotherapy with 0.310705 ganoderma lucidum 0.95261 Coriolus versicolor 0.338242 Ganoderma lucidum from 0.330019 triterpenoids from ganoderma 0.34341 from ganoderma spp 0.316446 extracted from ganoderma 0.316294 Se-enriched Ganoderma lucidum 0.325078 mushroom ganoderma lucidum 0.326878 cuáles pacientes 0.311657 adjuvant immunochemotherapy 0.310969 cells with immuno-stimulatory 0.308341 PSK may 0.326201 polysaccharides from ganoderma 0.316147 Ganoderma lucidum induces 0.347342 Oncol Rep 0.321721 Ganoderma lucidum polysaccharides 0.378912 Ganoderma lucidum mycelia 0.327066 pacientes supervivencia 0.312919 Ganoderma polysaccharides with 0.315786 patients with 0.347196 protein-bound polysaccharide psk 0.327993 lz-8 from ganoderma 0.316148 Ganoderma lucidum activities 0.328306 metabolites from ganoderma 0.315749	ganoderma lingzhi wu 0.315644 PSK quizás 0.327997 Ganoderma lucidum spores-induced 0.32738 from ganoderma lucidum 0.482816 oficiales ganoderma lucidum 0.327352 immunochemotherapy with psk 0.347115 PSK therapies 0.324706 isolated from ganoderma 0.330138 commercial ganoderma 0.31277 lucidum suppresses angiogenesis 0.315879 Ganoderma based 0.312698 ganoderma sinense zhao 0.315248 Mol Med 0.308288 gastric cancer 0.374999 extract from ganoderma 0.316948 immunochemotherapy with polysaccharide 0.311361 breast cancer 0.314008 Mushroom Science 0.307833 Ganoderma lingzhi from 0.316096 ganoderma lucidum triterpenoids 0.328168 PSK potencia 0.327619 Ganoderma lingzhi 0.323758 leukemia cells 0.314028 estudios cáncer 0.308153	CLICK HERE